title: Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers.
abstract: Aromatase inhibitors (AIs) are routinely used for the adjuvant treatment of women with hormone receptor-positive early breast cancer. AIs are widely prescribed in the postmenopausal setting, as they are effective at preventing recurrence. However, their use is complicated by significant adverse effects, particularly arthralgia, noted in up to 50% of treated patients, and thereby affects quality of life and AI compliance. The mechanism by which AIs cause arthralgia is largely unknown, although there is a growing body of literature which suggests that there may be multiple intersecting mechanisms. Areas covered: This review describes the evidence for the mechanistic basis of AI arthralgia as well as potential pathways that could contribute to the development of AI associated arthralgia. Expert opinion: Interplay of multiple factors, such as interpatient variability in AI metabolism, possibly related to pharmacogenetic factors, the sudden decline of estrogen synthesis, vitamin D status, as well as upregulation of cytokines and inflammation pathways may precipitate or exacerbate muscle and joint pain are linked during AI therapy. However, much more research is needed in this area given the frequency and severity of AI-associated arthralgia.
authors.affiliation: a Division of Clinical Pharmacology, Department of Medicine , Western University , London , ON , Canada.|b Department of Physiology and Pharmacology , Western University , London , ON , Canada.
authors.forename: Adrienne E
authors.initials: AE
authors.lastname: Borrie
authors.affiliation: a Division of Clinical Pharmacology, Department of Medicine , Western University , London , ON , Canada.|b Department of Physiology and Pharmacology , Western University , London , ON , Canada.
authors.forename: Richard B
authors.initials: RB
authors.lastname: Kim
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects*; D047072:Aromatase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D018771:Arthralgia / Q000139:chemically induced* / Q000235:genetics / Q000473:pathology; D015415:Biomarkers / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D055118:Medication Adherence; D010597:Pharmacogenetics; D011788:Quality of Life
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D015415:Biomarkers
keywords: Adverse drug reactions; aromatase inhibitors; arthralgia; pharmacokinetics